HIGHLIGHTS
- who: Haibo Wang and colleagues from the Emory, United States have published the Article: RecurIndex assay as an aid for adjuvant chemotherapy decisions in HR-positive HER2-negative breast cancer patients, in the Journal: (JOURNAL)
- what: The authors leveraged RecurIndex assay to stratify Chinese patients with HR-positive HER2-negative EBC as high and low groups and compared their survival outcomes according to the presence or absence of adjuvant chemotherapy, thus guiding the clinical decision-making on the use of adjuvant chemotherapy.
- how: In this study t test was used for comparison of . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.